GlassScriptPhysician profile
Alaina Payne
NPI 1194251942
$11,202.61
in general payments reported to CMS, 2019-2025
45 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $869 · 2021: $1,626 · 2022: $1,923 · 2023: $1,990 · 2024: $2,467 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,509 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,509.47 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,324.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,226.10 | 2021-2025 | |
| Pfizer INC. | $993.74 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $915.94 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $869.45 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $675.71 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $525.79 | 2020-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.38 | 2020-2025 | Jardiance |
| Exact Sciences Corporation | $432.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $362.65 | 2020-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.38 | 2020-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $268.00 | 2020-2024 | Trintellix |
| Dexcom, INC. | $246.39 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $221.92 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $190.78 | 2020-2023 | Eliquis |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $188.06 | 2020-2023 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $184.58 | 2022-2025 | |
| Esperion Therapeutics, INC. | $175.78 | 2022-2025 | Nexletol |
| Axsome Therapeutics, INC. | $168.62 | 2024-2025 | Auvelity |
| Vital Connect, INC | $152.44 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $144.42 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $100.46 | 2023-2025 | Gemtesa |
| Vanda Pharmaceuticals INC. | $89.56 | 2022-2023 | Hetlioz |
| Eisai INC. | $79.81 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $72.41 | 2020-2025 | Capvaxive, Gardasil 9 |
| Medtronic, INC. | $66.92 | 2024 | Intellis Adaptivestim |
| Boston Scientific Corporation | $66.39 | 2021-2025 | Wavewriter Alpha Prime 16, Ams 700 |
| Allergan, INC. | $62.88 | 2020 | |
| Amarin Pharma, INC. | $59.18 | 2020-2021 | |
| Edwards Lifesciences Corporation | $58.96 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Idorsia Pharmaceuticals US INC | $58.90 | 2023-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $50.53 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $43.96 | 2024 | Voquezna |
| Vivus LLC | $42.06 | 2021 | |
| Shield Therapeutics INC | $40.33 | 2025 | |
| Daiichi Sankyo INC. | $40.08 | 2021-2025 | Injectafer |
| Alkermes, INC. | $35.66 | 2024 | Vivitrol |
| Biohaven Pharmaceutical Holding Company LTD. | $31.37 | 2022 | |
| Abbott Laboratories | $29.55 | 2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $28.91 | 2024 | Ibsrela |
| Intuity Medical INC | $23.65 | 2022 | |
| Dynavax Technologies Corporation | $17.96 | 2024 | Heplisav-B |
| Harmony Biosciences LLC | $15.15 | 2024 | |
| Gilead Sciences, INC. | $14.82 | 2020 | |
| Endo Pharmaceuticals INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaina Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.